Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases

• DOI: 10.1016/j.ajpath.2015.09.018
• Publication Date: 2015-12-21T03:15:18Z
• Authors: Tina Bilousova; Carol A. Miller; Wayne W. Poon; Harry V. Vinters; Maria Corrada; Claudia Kawas; Eric Y. Hayden; David B. Teplow; Charles Glabe; Ricardo Albay; Gregory M. Cole; Edmond Teng; Karen H. Gylys
• Keywords: Male; Aging; Biomedical and clinical sciences; Enzyme-Linked Immunosorbent Assay; tau Proteins; Neurodegenerative; Alzheimer's Disease; Medical and Health Sciences; Transgenic; 03 medical and health sciences; 0302 clinical medicine; Alzheimer Disease; Health Sciences; Acquired Cognitive Impairment; 80 and over; Pathology; 2.1 Biological and endogenous factors; Animals; Humans; Aetiology; Phosphorylation; Aged; Aged, 80 and over; Microscopy; Amyloid beta-Peptides; Microscopy, Confocal; Biomedical and Clinical Sciences; Animal; Neurosciences; Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD); Health sciences; Brain; Flow Cytometry; Brain Disorders; Rats; 3. Good health; Disease Models, Animal; Confocal; Neurological; Disease Models; Synapses; Dementia; Female; Rats, Transgenic

Amyloid-β (Aβ) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of Alzheimer disease (AD), and oligomeric assemblies of each protein are localized to synapses. To determine the sequence by which pathology appears in synapses, Aβ and p-tau were quantified across AD disease stages in parietal cortex. Nondemented cases with high levels of AD-related pathology were included to determine factors that confer protection from clinical symptoms. Flow cytometric analysis of synaptosome preparations was used to quantify Aβ and p-tau in large populations of individual synaptic terminals. Soluble Aβ oligomers were assayed by a single antibody sandwich enzyme-linked immunosorbent assay. Total in situ Aβ was elevated in patients with early- and late-stage AD dementia, but not in high pathology nondemented controls compared with age-matched normal controls. However, soluble Aβ oligomers were highest in early AD synapses, and this assay distinguished early AD cases from high pathology controls. Overall, synapse-associated p-tau did not increase until late-stage disease in human and transgenic rat cortex, and p-tau was elevated in individual Aβ-positive synaptosomes in early AD. These results suggest that soluble oligomers in surviving neocortical synaptic terminals are associated with dementia onset and suggest an amyloid cascade hypothesis in which oligomeric Aβ drives phosphorylated tau accumulation and synaptic spread. These results indicate that antiamyloid therapies will be less effective once p-tau pathology is developed.